Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

ABSTRACT: The purpose of this study is to investigate the effects of nivolumab when given under the skin with or without rHuPH20. This study will include participants with 1 of the following advanced or metastatic tumors approved for treatment with nivolumab monotherapy: * non-small cell lung cancer (NSCLC) * renal cell carcinoma (RCC) * unresectable or metastatic melanoma * hepatocellular carcinoma (HCC) * microsatellite instability-high or mismatch repair deficient colorectal cancer (MSI-H/dMMR CRC) * in Part B, other solid tumors may be considered at the discretion of the Clinical Trial Physician * In addition to the above tumors, Part E will also include participants with metastatic urothelial carcinoma (mUC).

DISEASE(S): The Study Population Will Include Participants With 1 Of The Followingadvanced Or Metastatic Tumors Approved For Treatment With Nivolumab Monotherapy: Non-small Cell Lung Cancer (nsclc); Renal Ce...,Non-small Cell Lung Cancer,Colorectal Cancer,Neoplasms By Site,Metastatic Melanoma,The Study Population Will Include Participants With 1 Of The Following advanced Or Metastatic Tumors Approved For Treatment With Nivolumab Monotherapy: Non-small Cell Lung Cancer (nsclc); Renal Cell Carcinoma (rcc); Unresectable Or Metastatic Melanoma; Hepatocellular Carcinoma (hcc); Microsatellite Instability-high Or Mismatch Repair-deficient Colorectal Cancer (msi-h/dmmr Crc); Or Metastatic Urothelial Carcinoma (muc [part E Only]).,Urothelial Carcinoma,Renal Cell Carcinoma,Hepatocellular Carcinoma

PROVIDER: 2283030 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Project description:This is a Phase 1/2, open label study. Phase 1 consists of 2 parts. Part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors and lymphomas. Part 2 will evaluate the safety and tolerability of epacadostat in combination with nivolumab and chemotherapy in subjects with squamous cell carcinoma of head and neck (SCCHN) and non-small cell lung cancer (NSCLC). Phase 2 will include expansion cohorts in 7 tumor types, including melanoma, NSCLC, SCCHN, colorectal cancer, ovarian cancer, glioblastoma and diffuse large B-cell lymphoma (DLBCL).

| 2181052 | ecrin-mdr-crc

Clonal Evolution of Platinum-Resistant Metastatic Urothelial Cancer

Project description:<p>Using whole-exome sequencing of urothelial carcinoma samples including matched sets of primary and locally recurrent or metastatic UC tumors collected over time and space and an in-depth analysis of tumors from two rapid autopsies, we provide the first detailed analysis of the therapy-driven clonal evolution of platinum-resistant urothelial carcinoma.</p> <p>We performed a systematic and integrated analyses for the molecular characterization of high-grade upper tract urothelial carcinomas (UTUC) using the whole-exome and mRNA sequencing. </p>

| phs001087 | dbGaP

Homo sapiens

Project description:Hepatocellular carcinoma (HCC) tumors and cell lines

| PRJNA127971 | ENA

Oncogenic Functions of the Transcription Factor LSF

Project description:Overexpression of LSF in less aggressive hepatocellular carcinoma (HCC) cells resulted in highly aggressive, angiogenic and multi-organ metastatic tumors while inhibition of LSF significantly abrogated growth and metastasis of highly aggressive HCC cells in nude mice. We used microarrays to identify the downstream genes mediating the effects of LSF in HCC cells.

2010-04-06 | GSE19815 | GEO

Oncogenic Functions of the Transcription Factor LSF

2010-04-06 | E-GEOD-19815 | biostudies-arrayexpress

Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma

Project description:Novel perioperative strategies are needed to reduce recurrence rates in patients undergoing nephrectomy for high-risk, non-metastatic clear cell renal cell carcinoma (ccRCC). We conducted a prospective, phase I trial of neoadjuvant nivolumab prior to nephrectomy in 15 evaluable patients with non-metastatic ccRCC. We leveraged tissue from that cohort to elucidate the effects of PD-1 inhibition on immune cell populations in ccRCC and correlate the evolving immune milieu with anti-PD-1 response. We found that nivolumab durably induces a pro-inflammatory state within the primary tumor, and baseline immune infiltration within the primary tumor correlates with nivolumab responsiveness. Nivolumab increases CTLA-4 expression in the primary tumor, and subsequent nephrectomy increases circulating concentrations of sPD-L1, sPD-L3 (sB7-H3), and s4-1BB. These findings form the basis to consider neoadjuvant immune checkpoint inhibition (ICI) for high-risk ccRCC while the tumor remains in situ and provide the rationale for perioperative strategies of novel ICI combinations.

2023-12-18 | GSE245372 | GEO

4612f446-5e68-4aa3-b9b3-dc4620ae2004 - samples

Project description:RNAseq fastq files from 611 bulk pre-treatment tumors from two indications: metastatic urothelial bladder cancer patients (IMvigor210) and metastatic renal cell carcinoma (IMmotion150)

| EGAD00001006960 | EGA

A pilot study of the Bruton's tyrosine kinase inhibitor ibrutinib in combination with nivolumab in patients with metastatic solid tumors

Project description:Background: Preclinical work has demonstrated that ibrutinib inhibits the generation, migration and immunosuppressive function of myeloid-derived suppressor cells (MDSC). A pilot study tested the combination of ibrutinib and nivolumab in patients with metastatic solid tumors. Methods: Sixteen patients with metastatic solid malignancies were treated with ibrutinib (420 mg) daily and nivolumab (240 mg) IV on days 1 and 15 of 28 day cycles. Ibrutinib dosing started 7 days before cycle 1 of nivolumab and was given until cycle 1, day 8 of nivolumab. The effect of ibrutinib alone and in combination with nivolumab on circulating MDSC and immune subsets and cytokine/chemokine levels were measured. Single-cell RNA and TCR sequencing was also performed. Results: The most common treatment-related AEs were fatigue (31%) and anorexia (31%). Five patients had a clinical response (4 partial, 1 complete). Four patients had stable disease at 3 months. Median progression-free survival was 3.5 months and median overall survival 10.8 months. MDSC levels increased following 7 days of single-agent ibrutinib compared to baseline (21.91% vs. 27.67%). There was increased T cell proliferation in response (33.9% vs. 40.06%, p<0.01) to the combination regimen. Plasma levels of CCL2, CCL3, CCL4, CCL13, IL- 8, and VEGF-α decreased with ibrutinib treatment. Ibrutinib treatment altered the transcriptional state of the myeloid cell compartment and led to increased cancer-associated TCR clonotypes. Conclusion: The combination of ibrutinib and nivolumab was well tolerated and ibrutinib significantly impacted MDSC and T cell function in patients with solid metastatic tumors.

2022-06-24 | GSE178882 | GEO

DNA copy number gain at 1q23.3 is associated with poor survival in metastatic bladder cancer [Agilent]

Project description:Metastatic urothelial carcinoma (UC) of the bladder is associated with multiple somatic copy number alterations (SCNAs). We evaluated SCNAs to identify predictors of poor survival in patients with metastatic UC treated with platinum chemotherapy.

2013-07-07 | GSE39281 | GEO

DNA copy number gain at 1q23.3 is associated with poor survival in metastatic bladder cancer [Affymetrix]

2013-07-07 | GSE39280 | GEO